##### Table of Contents

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549





FORM 10-QSB



|(Mark One) |  |                                                                                                                                    
|---------- |  | -----------------------------------------------------------------------------------------------------------------------------------
|x          |  | Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2003
| ̈          |  | Transition report under Section 13 or 15(d) of the Exchange Act                                                                    



Commission file number:
33-55254-36



E Med Future, Inc.

---

(Exact name of small business issuer as specified in its charter)





|Nevada                   |  |  |  | 87-0485314                          
|------------------------ |  |  |  | ------------------------------------
|                         |  |  | 
|(State of incorporation) |  |  |  | (I.R.S. Employer Identification No.)



794 Morrison Road,
Suite 911, Columbus, OH 43230

---

(Address of principal executive offices)





877-855-1319

---

(Issuers telephone number)





Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.    Yes    x        No ̈



State the number of shares outstanding of each of the issuers classes of common equity, as of the latest practicable date: 24,884,000 shares of common stock, $0.001 par value per share, as of November 1, 2003



Transitional Small Business Disclosure Format (check
one):    Yes ̈No    x





---



---

##### Table of Contents

TABLE OF CONTENTS



|PART I  FINANCIAL INFORMATION             |  | 3                                                  
|------------------------------------------ |  | ---------------------------------------------------
|                                           |  |                                                    
|Item 1.                                    |  | Financial Statements                               
|                                           |  |                                                    
|Item 2.                                    |  | Managements Discussion and Analysis               
|                                           | 
|Our History                                |  | 9                                                  
|                                           | 
|Our Product                                |  | 9                                                  
|                                           | 
|Recent Events                              |  | 9                                                  
|                                           | 
|Results of Operation                       |  | 10                                                 
|                                           | 
|Third Quarter of 2003 Compared to 2002     |  | 10                                                 
|                                           | 
|First Nine Months of 2003 Compared to 2002 |  | 11                                                 
|                                           | 
|Financial Condition and Liquidity          |  | 11                                                 
|                                           | 
|Forward Looking Statements                 |  | 12                                                 
|                                           |  |                                                    
|Item 3.                                    |  | Controls and Procedures                            
|                                           | 
|PART II  OTHER INFORMATION                |  | 14                                                 
|                                           |  |                                                    
|Item 1.                                    |  | Legal Proceedings                                  
|                                           |  |                                                    
|Item 2.                                    |  | Changes in Securities and Use of Proceeds          
|                                           |  |                                                    
|Item 3.                                    |  | Defaults Upon Senior Securities                    
|                                           |  |                                                    
|Item 4.                                    |  | Submission of Matters to a Vote of Security Holders
|                                           |  |                                                    
|Item 5.                                    |  | Other Information                                  
|                                           |  |                                                    
|Item 6.                                    |  | Exhibits and Reports on Form 8-K                   
|                                           |  |                                                    
|(a)                                        |  | Exhibits                                           
|                                           |  |                                                    
|(b)                                        |  | Reports on Form 8-K                                
|                                           | 
|SIGNATURES                                 |  | 15                                                 



---

##### Table of Contents

PART I  FINANCIAL INFORMATION





Item 1.
Financial Statements





E MED FUTURE, INC.

Formerly
Micro-Economics, Inc.

(A Development Stage Company)



CONDENSED BALANCE SHEETS (UNAUDITED)



|ASSETS                                                                                                 |  |                    |           |  
|------------------------------------------------------------------------------------------------------ |  | ------------------ | --------- | -
|                                                                                                       |  | September 30, 2003 |          
|CURRENT ASSETS                                                                                         |  |                    |           |  
|Cash                                                                                                   |  | $                  | 2,911     |  
|Accounts receivable                                                                                    |  |                    | 226,246   |  
|Inventory                                                                                              |  |                    | 329,825   |  
|Prepaid expenses                                                                                       |  |                    | 24,706    |  
|                                                                                                       |  |                    |           |  
|Total Current Assets                                                                                   |  |                    | 583,688   |  
|PROPERTY AND EQUIPMENT, net                                                                            |  |                    | 126,531   |  
|PATENTS, net of amortization                                                                           |  |                    | 155,907   |  
|                                                                                                       |  |                    |           |  
|                                                                                                       |  | $                  | 866,126   |  
|                                                                                                       |  |                    |           |  
|LIABILITIES AND STOCKHOLDERS EQUITY                                                                   |  |                    |           |  
|CURRENT LIABILITIES                                                                                    |  |                    |           |  
|Note payable to bank                                                                                   |  | $                  | 141,098   |  
|Accounts payable                                                                                       |  |                    | 203,584   |  
|Accrued rent to related party                                                                          |  |                    | 37,800    |  
|Accrued expenses                                                                                       |  |                    | 42,849    |  
|Notes payable to related parties                                                                       |  |                    | 292,585   |  
|                                                                                                       |  |                    |           |  
|Total Current Liabilities                                                                              |  |                    | 717,916   |  
|STOCKHOLDERS EQUITY                                                                                   |  |                    |           |  
|Common stock, $0.001 par value, 50,000,000 shares authorized; 24,884,000 shares issued and outstanding |  |                    | 24,884    |  
|Additional paid-in-capital                                                                             |  |                    | 1,112,382 |  
|Deficit accumulated during development stage                                                           |  |                    | (989,056  | )
|                                                                                                       |  |                    |           |  
|                                                                                                       |  |                    | 148,210   |  
|                                                                                                       |  |                    |           |  
|                                                                                                       |  | $                  | 866,126   |  
|                                                                                                       |  |                    |           |  



The accompanying notes
are an integral part of these financial statements.



3



---

##### Table of Contents

E MED FUTURE, INC.

Formerly Micro-Economics, Inc.

(A Development Stage Company)



STATEMENTS OF OPERATIONS (UNAUDITED)



|                                            |  | Three Months EndedSeptember 30, |         |   | Nine Months EndedSeptember 30, |   |          | For the PeriodMarch 14, 1990(Inception) toSeptember 30,2003 | 
|------------------------------------------- |  | ------------------------------- | ------- | - | ------------------------------ | - | -------- | ----------------------------------------------------------- | 
|                                            |  | 2003                            |         |   | 2002                           |   |          | 2003                                                        | 
|SALES                                       |  | $                               | 96,094  |   |                                | $ | 2,320    |                                                             | 
|COST OF SALES                               |  |                                 | 54,346  |   |                                |   | 32,443   |                                                             | 
|                                            |  |                                 |         |   |                                |   |          |                                                             | 
|GROSS PROFIT (LOSS)                         |  |                                 | 41,748  |   |                                |   | (30,123  | )                                                           | 
|ADMINISTRATIVE EXPENSES                     |  |                                 |         |   |                                |   |          |                                                             | 
|General administrative expenses             |  |                                 | 84,507  |   |                                |   | 79,798   |                                                             | 
|Stock based compensation                    |  |                                 |        |   |                                |   |         |                                                             | 
|Depreciation and amortization               |  |                                 | 7,330   |   |                                |   | 6,718    |                                                             | 
|                                            |  |                                 |         |   |                                |   |          |                                                             | 
|Total administrative expenses               |  |                                 | 91,837  |   |                                |   | 86,516   |                                                             | 
|                                            |  |                                 |         |   |                                |   |          |                                                             | 
|NET INCOME (LOSS)                           |  | $                               | (50,089 | ) |                                | $ | (116,639 | )                                                           | 
|                                            |  |                                 |         |   |                                |   |          |                                                             | 
|NET LOSS PER COMMON SHARE-BASIC AND DILUTED |  | $                               | (0.01   | ) |                                | $ | (0.01    | )                                                           | 
|                                            |  |                                 |         |   |                                |   |          |                                                             | 
|WEIGHTED AVERAGE SHARES OUTSTANDING         |  |                                 |         |   |                                |   |          |                                                             | 
|                                            |  |                                 |         |   |                                |   |          |                                                             | 



The accompanying notes
are an integral part of these financial statements.



4



---

##### Table of Contents

E MED FUTURE, INC.

Formerly Micro-Economics, Inc.

(A Development Stage Company)



STATEMENTS OF CASH FLOWS (UNAUDITED)



|                                                                                   |  | Nine Months EndedSeptember 30, |          |   | For the PeriodMarch 14, 1990(Inception) toSeptember 30,2003 |  
|---------------------------------------------------------------------------------- |  | ------------------------------ | -------- | - | ----------------------------------------------------------- | -
|                                                                                   |  | 2003                           |          |   | 2002                                                        |  
|CASH FLOWS FROM OPERATING ACTIVITIES                                               |  |                                |          |   |                                                             |  
|Net loss                                                                           |  | $                              | (608,429 | ) |                                                             | $
|Adjustments to reconcile net loss to net cash used in operating activities:        |  |                                |          |   |                                                             |  
|Start up costs                                                                     |  |                                |         |   |                                                             |  
|Stock based compensation                                                           |  |                                | 600,000  |   |                                                             |  
|Depreciation and amortization                                                      |  |                                | 21,684   |   |                                                             |  
|Research and development costs                                                     |  |                                |         |   |                                                             |  
|Amortization of prepaid expense                                                    |  |                                | 8,925    |   |                                                             |  
|Changes in operating assets and liabilities                                        |  |                                |          |   |                                                             |  
|Accounts receivable                                                                |  |                                | (222,246 | ) |                                                             |  
|Inventory                                                                          |  |                                | (156,337 | ) |                                                             |  
|Prepaid expenses                                                                   |  |                                | 160      |   |                                                             |  
|Accounts payable                                                                   |  |                                | 149,574  |   |                                                             |  
|Accrued expenses                                                                   |  |                                | 59,400   |   |                                                             |  
|                                                                                   |  |                                |          |   |                                                             |  
|NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES                                |  |                                | (147,269 | ) |                                                             |  
|                                                                                   |  |                                |          |   |                                                             |  
|CASH FLOWS FROM INVESTING ACTIVITIES                                               |  |                                |          |   |                                                             |  
|Purchase of property and equipment/patents                                         |  |                                | (6,703   | ) |                                                             |  
|                                                                                   |  |                                |          |   |                                                             |  
|NET CASH USED IN INVESTING ACTIVITIES                                              |  |                                | (6,703   | ) |                                                             |  
|                                                                                   |  |                                |          |   |                                                             |  
|CASH FLOWS FROM FINANCING ACTIVITIES                                               |  |                                |          |   |                                                             |  
|Initial capitalization                                                             |  |                                | 1,666    |   |                                                             |  
|Proceeds from note payable to bank                                                 |  |                                | 65,000   |   |                                                             |  
|Proceeds from notes payable to related parties                                     |  |                                | 77,000   |   |                                                             |  
|                                                                                   |  |                                |          |   |                                                             |  
|NET CASH PROVIDED BY FINANCING ACTIVITIES                                          |  |                                | 143,666  |   |                                                             |  
|                                                                                   |  |                                |          |   |                                                             |  
|NET (DECREASE) INCREASE IN CASH                                                    |  |                                | (10,306  | ) |                                                             |  
|CASH AND CASH EQUIVALENTS  Beginning                                              |  |                                | 13,217   |   |                                                             |  
|                                                                                   |  |                                |          |   |                                                             |  
|CASH AND CASH EQUIVALENTS  Ending                                                 |  | $                              | 2,911    |   |                                                             | $
|                                                                                   |  |                                |          |   |                                                             |  
|SUPPLEMENTAL SCHEDULE OF NON-CASH OPERATING AND FINANCING ACTIVITIES               |  |                                |          |   |                                                             |  
|Needle Zap Partnership contribution of assets to company                           |  |                                |          |   |                                                             |  
|Inventory                                                                          |  |                                |         |   |                                                             |  
|Equipment                                                                          |  |                                |         |   |                                                             |  
|Patent                                                                             |  |                                |         |   |                                                             |  
|Issuance of 34,000 shares valued at $.90 purchase for Strategic Alliance Agreement |  | $                              | 30,600   |   |                                                             |  



The accompanying notes
are an integral part of these financial statements.



5



---

##### Table of Contents

E MED FUTURE, INC.

Formerly Micro-Economics, Inc.

(A Development Stage Company)



NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS



NOTE 1    BASIS OF PRESENTATION



The accompanying condensed consolidated financial statements
have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary in order to make the financial statements not misleading have been included. Results for the nine months ended
September 30, 2003 are not necessarily indicative of the results that may be expected for the year ending December 31, 2003. For further information, refer to the financial statements and footnotes thereto included in the E Med Future, Inc.,
formerly Micro-Economics, Inc., annual report on Form 10-KSB for the year ended December 31, 2003 and Notes 2-7 of Notes to Unaudited Condensed Financial Statements.



NOTE 2    DESCRIPTION OF BUSINESS



The Company and Nature of Business

E Med Future, Inc. (the Company), a development stage enterprise, was organized under the laws of Delaware on August 25, 2000. The Company
plans to manufacture and sell a device that can disable a hypodermic needle trademarked under the name Needle Zap. The Company had no operating activities from inception to December 31, 2000.



Reverse Merger

On April 2003, Micro-Economics, Inc. (Micro), a Nevada corporation, acquired all of the Companys outstanding convertible
preferred stock by the issuance of 19,850,000 shares of $0.001 par value common stock (the Merger). Simultaneously, Micro-Economics, Inc. changed its name to E Med Future, Inc. In connection with the Merger, the Company became a wholly
owned subsidiary of Micro and the Companys officers and directors replaced Micros officers and directors. Prior to the Merger, Micro was a non-operating shell corporation. Pursuant to Securities and Exchange Commission rules,
the Merger of a private operating company (E Med Future, Inc.) into a non-operating public shell corporation with nominal net assets (Micro) is considered a capital transaction. Accordingly, for accounting purposes, the Merger has been treated as an
acquisition of Micro by the Company and a recapitalization of the Company. The historical financial statements prior to April 4, 2003 are those of the Company.



NOTE 3    GOING CONCERN UNCERTAINTY AND MANAGEMENTS PLANS



As shown in the accompanying financial statements, the Company incurred a net loss of $608,429 during the
nine months ended September 30, 2003 resulting in a deficit accumulated during the development stage of $989,056. Additionally the Company has a negative working capital of $134,228. The Company has received Food and Drug Administration (FDA)
approval for its product as well as its manufacturing facility.



6



---

##### Table of Contents

E MED FUTURE, INC.

Formerly Micro-Economics, Inc.

(A Development Stage Company)



NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS (CONTINUED)



NOTE 3    GOING CONCERN UNCERTAINTY
AND MANAGEMENTS PLANS (CONTINUED)



Managements
plans include developing a marketing plan and sales force to market its product domestically and internationally. The Company may also have to obtain additional short-term financing to accomplish its sales and marketing plans. These matters raise
substantial doubt about the Companys ability to continue as a going concern. However, the accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of
liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to
continue as a going concern.



NOTE
4    ACQUISITION OF OPERATING ASSETS



On February 8, 2001, the Company signed an agreement with NeedleZap Partners, an Ohio General Partnership whereby the Partnership transferred all of its assets to the Company in exchange for shares of the Companys stock and a royalty
arrangement. An allocation of the purchase price was as follows:



|Fair value of net assets acquired |  |         
|--------------------------------- |  | --------
|Inventory                         |  | $151,015
|Equipment                         |  | 133,912 
|Patent                            |  | 187,089 
|Research and development costs    |  | 8,807   
|Start up costs                    |  | 19,177  
|                                  |  |         
|                                  |  | $500,000
|                                  |  |         



NOTE
5    PATENT



The Company acquired a
registered patent to produce the device that will disable a hypodermic needle. The total value assigned to the patent is $187,089 and is being amortized on a period of 15 years. Annual amortization for each of the succeeding five years will be
approximately $12,500.



NOTE
6    ROYALTY AGREEMENT



The Company
has entered into a royalty arrangement with NeedleZap General Partnership. Commencing on December 1, 2000, the Company agreed to develop, manufacture and market NeedleZap units. For every unit sold, the Company agreed to pay the Partnership a
royalty of $5.00 until one million units are sold and/or all royalties are paid on or before July 1, 2002. The term of this agreement was automatically extended and, further, the requirement to pay a $5.00 royalty on each unit sold was increased
from one million units to five million units regardless of how long it takes the company to sell five million units. Additionally, the Company has agreed to pay $1.00 per unit sold which will be divided amongst two officers of the Company and the
Director of Research and Development.



7



---

##### Table of Contents

E MED FUTURE, INC.

Formerly Micro-Economics, Inc.

(A Development Stage Company)



NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS (CONTINUED)



NOTE 7    RELATED PARTY
TRANSACTIONS



The Company has an informal lease
arrangement with the President of the Company to provide administrative office space. The arrangement requires a monthly payment of $1,800. The lease arrangement has been in effect since January 1, 2002 and is on a month to month basis.



NOTE 8    STOCKHOLDERS
EQUITY



On April 21, 2003, the Board of Directors
authorized the issuance of 4,000,000 shares of its common stock to various consultants for prior services rendered. These shares have been valued at a discounted market price of $0.15 per share and have accordingly been treated as stock based
compensation aggregating $600,000.



NOTE
9    STRATEGIC ALLIANCE AGREEMENT



On June 12, 2003, the Board of Directors authorized the issuance of 34,000 shares of its common stock for services to be rendered, during a 12 month period commencing June 12, 2003, under a Strategic Alliance Agreement wherein UTEK
Corporation will use its best efforts to identify new technologies that could be acquired by the company. These shares have been valued at a discounted market price of $0.90 per share.



8



---

##### Table of Contents

Item 2.    
Managements Discussion and Analysis



Our History



The Company was formed under the laws
of the State of Nevada on March 14, 1990, but until this year we were a shell company with no significant operations other than seeking to identify an existing business to acquire. Trading in our stock was dependant on our acquisition of an
operating business. On April 4, 2003, we participated in a merger in which we acquired E Med Future, Inc., a Columbus, Ohio-based distributor of the NeedleZap®, a safety device intended to help reduce accidental hypodermic needlesticks by disintegrating the sharp portion of the
needle. In connection with the transaction, we issued 19,850,000 unregistered shares of our common stock (95% of our outstanding shares) to the former stockholders of E Med Future.



Pursuant to the terms of the merger agreement, we changed our corporate name from Micro-Economics, Inc. to E Med Future,
Inc. In addition, our original directors resigned and were replaced by Robert J. Ochsendorf, D. Dane Donohue and Juan J. Perez. Messrs. Ochsendorf and Donohue now serve as our President and Executive Vice President, respectively. Our shares
began trading on the Over-the-Counter Bulletin Board under the symbol EMDF.OB on April 17, 2003. For additional information about the merger, please see the Current Report on Form 8-K dated April 4, 2003 that we filed with the SEC on
April 11, 2003.



Our Product



Our primary product is the
NeedleZap®, a revolutionary safety device intended
to help reduce accidental needlestick injuries in the workplace by disintegrating the sharp portion of a hypodermic needle. When a hypodermic needle is inserted into the unit, the patented electrode system disintegrates the needle in approximately
two seconds at 2200° F, leaving the syringe intact. According to the American Nursing Association, there are an estimated one million accidental needlesticks reported in the United States in the healthcare industry alone. We believe the
applications for the product are far reaching, and include healthcare professionals, law enforcement personnel, clinical researchers and sanitation workers. We currently have worldwide distribution contracts with American Health & Safety
Products, Inc., and its wholly owned subsidiary, AHSP International L.L.C., which have representation in the United States, Europe, China, South America, Central America and Canada.



Recent Events



In August, we announced our
expansion into Uganda through a distribution partner in Africa, Global Marketing Group. Global Marketing is currently working with Ugandan-based Lily Pharmacy (U) Ltd. to market the NeedleZap® unit to hospitals, clinics and pharmacies throughout Uganda. Since 1974, Lily has been
importing pharmaceuticals and medical supplies for wholesale and retail distribution. Lily Pharmacy is not affiliated with Eli Lilly and Company.



In October, our sales and marketing partner, American Health & Safety Products, secured an agreement with Mercury Medical to distribute NeedleZap® to the medical/surgical market. Mercury Medical is a
medical products distributor and manufacturer, concentrating on the critical care areas of the hospital, physician office, clinic, surgery center and homes with oxygen/durable medical equipment and supplies. As part of the agreement, Mercury Medical
will have the exclusive rights to distribute NeedleZap® to the 140 dealer members of the



9



---

##### Table of Contents

Independent Medical Co-Op (IMCO), a leading co-op for medical supply distributors targeting physicians, hospitals, nursing homes, home health, EMS,
industrial and other related markets.



In November, we announced that American
Health & Safety Products had secured an agreement with National Distribution & Contracting, Inc. to distribute NeedleZap® to the medical/surgical market through their StarLine, ABCO, and CIDA distributor members. The agreement also includes the NeedleZap® dental unit, currently under development, which will be
marketed to the dental industry through National Distribution & Contractings ADC and UDD members once FDA approval is obtained.



Results of Operation



In December 2001, we filed a
pre-market approval application, or PMA, with The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for NeedleZap®. On the basis of counsels advice, we determined that NeedleZap® was not regulated by the CDRH as a medical device in veterinarian or law enforcement applications. Therefore, we opted
to market NeedleZap® in the United States to
veterinarians and law enforcement professionals. Revenues generated from these sales would offset the costly and lengthy FDA approval process and provide funding for promotion, tooling, parts and the overall operations.



In July 2002, we received an approvable letter from the FDA stating that NeedleZap® met all the requirements for the safety and
effectiveness data testing for a Class 3 medical device. The approvable letter was subject to an FDA inspection that found the manufacturing facilities, methods and controls in compliance with the applicable requirements of FDA quality system
regulation. During the manufacturing inspectional phase in August 2002, the FDA requested that we suspend all sales to veterinarian and law enforcement markets until the product was fully approved. We voluntarily complied with the FDAs request
and suspended all sales in U.S. markets.



On March 14, 2003, the FDA issued a
final approval order letter for NeedleZap®. Final
labeling was submitted and approved on March 19, 2003, clearing the way to market NeedleZap® in the United States in health care facilities and treatment settings.



With all regulatory matters resolved, we anticipate an increase in sales in the coming quarters. Because we did not have full approval to market and sell our products
until March 2003, we do not believe a detailed comparison of results from the first nine months of 2003, to the same period in 2002 to be informative.



Third Quarter of 2003 Compared to 2002



Our sales
increased $93,774 to $96,094 in the third quarter of 2003 from $2,320 in the same period of 2002. This increase is primarily attributable to sales following the FDAs approval of NeedleZap® in March 2003 and the addition of international distribution channels through American
Health & Safety Products. Although sales increased, we continued to devote most of our efforts during the third quarter to presenting our product to major medical distributors for evaluation.



10



---

##### Table of Contents

Our gross profit was $41,748 in the third quarter of 2003 compared to a loss of $30,123 in 2002. This improvement was
caused by an increase in sales only partially offset by an increase in the cost of sales. The relative decrease in the cost of sales as a percentage of sales was primarily the result of the implementation of our new sales channel, American Health
& Safety Products, Inc., which was not operational in 2002.



Administrative
expenses increased $5,321, or 6.2%, to $91,837 in the third quarter of 2003 from $86,516 in the same quarter of 2002. The increase was primarily caused by higher general administrative expenses necessary to comply with FDA requirements.



As a result of the factors described above, we had a net loss of $50,089 in the third
quarter of 2003, compared to a net loss of $116,639 for the same period of 2002.



First Nine Months of 2003 Compared to 2002



We had
sales of $343,623 in the first nine months of 2003, compared with $234,392 in the same period of 2002, an increase of $109,231 or 46.6%. This increase is primarily attributable to sales following the FDAs approval of NeedleZap® in March 2003.



Our gross profit increased $175,967 to $221,408 in the first three quarters of 2003 compared
to $45,441 in 2002. Our improved profitability was caused by an increase in sales coupled with a reduction in the cost of sales. The reduction in the cost of sales was primarily the result of the implementation of the American Health & Safety
Products sales channel in 2003.



Administrative expenses increased $633,846 to
$829,837 in the first nine months of 2003 from $195,991 for the same period of 2002. The increase was primarily caused by $600,000 in stock based compensation expenses in the first quarter of 2003 as a result of our issuance of four million shares
in April as compensation for consulting services previously rendered.



As a
result of the factors described above, our net loss increased to $608,429 or $0.03 a share, in the first three quarters of 2003, from a net loss of $150,550, or $0.01 a share, for the same period of 2002.



Financial Condition and Liquidity



We had
available cash of $2,911 on September 30, 2003. Cash used in operations remained steady at $147,269 for the first nine months of 2003 compared to $146,668 for the first nine months of last year.



On November 12, 2002, we entered into a credit facility with KeyBank (NA). The facility
provides us with a working capital line-of-credit of up to $150,000 and bears interest at 4.75%. The credit facility is secured by all of E Meds assets and must be paid back in full on demand. We presently have drawn $141,098 on the facility.



Our primary need for capital is to fund operations and the development of new
products. Historically, our capital requirements have been met by a combination of loans from stockholders, our line of credit with Key Bank, and funds from operations. Now that we have obtained FDA approval for NeedleZap® and our distributors have had sufficient ramp-up time, we expect increased
sales to meet our capital needs. In addition, we are developing new



11



---

##### Table of Contents

NeedleZap® products to help generate additional revenues. However, sales may not be adequate to meet our cash needs, which would negatively impact our operations
and development of new and ancillary products. For an overview of the risks we face, please see Forward Looking Statements below.



Forward Looking Statements



Some of the
statements that we make in this report, including statements about our confidence in E Meds prospects and strategies and our expectations about E Meds sales expansion, are forward-looking statements within the meaning of § 21E of
the Securities Exchange Act. Some of these forward-looking statements can be identified by words like believe, expect, will, should, intend, plan, or similar terms; others can
be determined by context. Statements contained in this report that are not historical facts are forward-looking statements. These statements are necessarily estimates reflecting our best judgment based upon current information, and involve a number
of risks and uncertainties. Many factors could affect the accuracy of these forward-looking statements, causing our actual results to differ significantly from those anticipated in these statements. While it is impossible to identify all applicable
risks and uncertainties, they include:



| |  | our ability to execute our business plan;
|- |  | -----------------------------------------



| |  | our ability to successfully market and sell our products;
|- |  | ---------------------------------------------------------



| |  | our ability to gain and retain market share from our competitors, many of whom have greater financial and other resources than we do;
|- |  | -------------------------------------------------------------------------------------------------------------------------------------



| |  | the introduction of competing products by other firms;
|- |  | ------------------------------------------------------



| |  | our ability to protect our patents, copyrights and other intellectual property rights;
|- |  | --------------------------------------------------------------------------------------



| |  | pressure on pricing from our competitors or customers;
|- |  | ------------------------------------------------------



| |  | continued availability of components for our products and stability in the cost of these components;
|- |  | ----------------------------------------------------------------------------------------------------



| |  | our reliance on subcontractors to manufacture our products;
|- |  | -----------------------------------------------------------



| |  | our financial resources are limited and we are dependant on increasing sales to generate cash for operations; and
|- |  | -----------------------------------------------------------------------------------------------------------------



| |  | our ability to continue to comply with rules and regulations governing our products.
|- |  | ------------------------------------------------------------------------------------



You should not place undue reliance on our forward-looking statements, which reflect our analysis only as of the date of this report. The
risks and uncertainties listed above and elsewhere in this report and other documents that we file with the Securities and Exchange Commission, including our annual report on Form 10-KSB, quarterly reports on Form 10-QSB, and any current reports on
Form 8-K, must be carefully considered by any investor or potential investor in E Med.



12



---

##### Table of Contents

Item 3. Controls and Procedures



Robert J.
Ochsendorf, our President and Chief Executive Officer, and D. Dane Donohue, our Executive Vice President, have reviewed E Meds disclosure controls and procedures as of September 30, 2003. Based upon their review, they believe that our
disclosure controls and procedures are effective in ensuring that material information related to E Med is communicated to them by others within the company responsible for reporting this information.



13



---

##### Table of Contents

PART II  OTHER INFORMATION





Item 1.    
Legal Proceedings



Not applicable.



Item 2.    
Changes in Securities and Use of Proceeds



Not
applicable.



Item 3.    
Defaults Upon Senior Securities



Not applicable.



Item 4.    
Submission of Matters to a Vote of Security Holders



Not applicable.



Item 5.    
Other Information



Not applicable.



Item 6.    
Exhibits and Reports on Form 8-K



|     | 
|---- | 
|(a)  | 
|     | 
|31.1 | 
|     | 
|31.2 | 
|     | 
|32.1 | 
|     | 
|(b)  | 



On July 14, 2003, we filed a Current
Report on Form 8-K dated July 2, 2003 reporting that we had dismissed Smith & Company as our independent auditors and appointed Meyler & Company, LLC to serve in that capacity.



14



---

##### Table of Contents

SIGNATURES



In accordance with the requirements of
the Exchange Act, E Med Future, Inc. caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



|                         |  |  |  | E MED FUTURE, INC.                          
|------------------------ |  |  |  | --------------------------------------------
|                         |  | 
|Date:  November 13, 2003 |  |  |  | /s/    D. DANE DONOHUE                      
|                         |  |  | 
|                         |  |  |  | By D. Dane Donohue, Executive Vice President



15